Labcorp Holdings Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the U.S. Securities and Exchange Commission on October 30, 2026, reporting third-quarter revenue of $3,810.0 million and diluted earnings per share of $3.22.

Key Highlights

  • Quarterly revenue of $3,810.0 million for the three months ended September 30, 2026, compared to $3,563.5 million in the same period of 2025, according to the filing.
  • Net earnings attributable to Labcorp Holdings Inc. were $262.8 million for Q3 2026, versus $261.1 million in Q3 2025, per the condensed consolidated statements of operations.
  • Diluted EPS of $3.22 for the three months ended September 30, 2026, compared to $3.12 in the prior-year quarter, as reported in the filing.
  • Nine-month revenue of $11,078.7 million through September 30, 2026, up from $10,435.9 million for the same period in 2025, the company disclosed.
  • Total assets of $18,924.6 million as of September 30, 2026, compared to $18,392.7 million at December 31, 2025, per the balance sheet.
  • 81.2 million shares of common stock outstanding as of October 29, 2026, as stated on the cover page of the filing.

Labcorp Holdings Q3 2026 Financial Results and Balance Sheet Position

Labcorp Holdings Inc. (NYSE:LH), incorporated in Delaware and headquartered at 358 South Main Street, Burlington, North Carolina, reported third-quarter 2026 revenue of $3,810.0 million, an increase from $3,563.5 million in the third quarter of 2025, according to its unaudited condensed consolidated statements of operations. Gross profit for the quarter was $1,108.1 million, compared to $1,025.1 million in Q3 2025. Operating income for the three months ended September 30, 2026 was $402.1 million, versus $396.6 million in the comparable prior-year period, the company disclosed.

For the nine months ended September 30, 2026, the filing reported net earnings attributable to Labcorp Holdings Inc. of $839.3 million, compared to $711.8 million for the same period in 2025. Diluted earnings per share for the nine-month period were $10.22, up from $8.48 in the prior-year period. Restructuring and other charges were $27.4 million for the nine months ended September 30, 2026, compared to $16.4 million in the same period of 2025, according to the filing. Interest expense for the nine-month period was $175.3 million, versus $169.1 million a year earlier.

As of September 30, 2026, the company reported total assets of $18,924.6 million, total liabilities of $10,060.7 million, and total shareholders' equity of $8,847.8 million, per the unaudited condensed consolidated balance sheet. Long-term debt stood at $5,250.7 million at the end of the quarter, up from $5,084.6 million at December 31, 2025. Accumulated other comprehensive loss widened to $143.4 million at September 30, 2026, from $27.6 million at year-end 2025, reflecting foreign currency translation adjustments of negative $116.9 million for the nine-month period, as the filing disclosed.

What Was Disclosed

Labcorp Holdings Inc. filed its quarterly report for the period ended September 30, 2026, disclosing revenue, earnings, per-share results, balance sheet data, and cash flow information for the three and nine months ended September 30, 2026 and 2025.